newsfilter
← Latest News
Business Wire·

ImmunityBio Completes Acquisition of Athenex's Interest in Dunkirk, New York Advanced Biotech Manufacturing Facility

409,000 square foot, state-of-the-art facility expands capabilities for large-scale manufacture of vaccine and immunotherapy product candidates ImmunityBio, Inc. (NASDAQ:IBRX), a clinical-stage immunotherapy company ("ImmunityBio"), today announced t